CytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results

CytoSorbents Pre-announces Q4 2016 and

Full-Year 2016 Results

JUNCTION, NJ, January 10, 2017 - CytoSorbents Corporation

(NASDAQ: CTSO), a critical care immunotherapy leader commercializing

its flagship CytoSorb blood filter to treat deadly

inflammation in critically-ill and cardiac surgery patients around the world,

pre-announces unaudited Q4 2016 and Full-year 2016 results ahead of its Form 10-K filing.

2016 Financial Highlights:

Phillip Chan, Chief Executive Officer of CytoSorbents stated, "These results reflect the continued importance and momentum

of our CytoSorb therapy in hospitals around the world. In light of our recent partnership and reimbursement updates, we believe

we are well-positioned for a strong 2017."

About CytoSorbents Corporation (NASDAQ: CTSO)

Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb

is approved in the European Union with distribution in 42 countries around the world, as a safe and effective extracorporeal

cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise

cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury

and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective

treatments exist. CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators,

such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents

has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial - a multi-center, randomized controlled study that has demonstrated

the safety of intra-operative CytoSorb use in a heart-lung machine during complex cardiac surgery. In 2017, the

company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb has been used

safely in more than 20,000 human treatments to date.

purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances

from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant,

contract, and other funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Department of Health and Human

Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations

Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification

technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend ,

ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com

Forward-Looking Statements

press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private

Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our

plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such

as "may," "should," "could," "expect," "plan," "anticipate," "believe,"

"estimate," "predict," "potential," "continue" and similar words, although some forward-looking

statements are expressed differently. You should be aware that the forward-looking statements in this press release represent

management's current judgment and expectations, but our actual results, events and performance could differ materially from those

in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to,

the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported

in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time

to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not

to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any

forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under

the Federal securities laws.

Cytosorbents Contact:

Public Relations Contact:

Pascale Communications